Climb Bio Sees Unusually Large Options Volume (NASDAQ:CLYM)

Climb Bio, Inc. (NASDAQ:CLYM) was the target of unusually large options trading activity on Wednesday. Traders purchased 3,024 call options on the company. This is an increase of approximately 740% compared to the typical volume of 360 call options.

Key Headlines Impacting Climb Bio

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Climb Bio is advancing a Phase 2 trial in China, a potentially important step for its clinical program and future commercial opportunities. The development provides a fundamental catalyst, although investors may be waiting for additional trial data. Climb Bio Advances Phase 2 Trial in China
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $24 price target, above the stock’s recent trading level. The firm also improved its loss estimates, forecasting a 2026 loss of $0.76 per share versus $0.93 previously, with smaller projected quarterly losses of $0.20 in Q3 and $0.19 in Q4.
• Neutral Sentiment: The valuation may already reflect much of the optimism surrounding the China trial and the company’s broader pipeline. Climb Bio trades near its 12-month high, while it remains unprofitable; the consensus forecast calls for a $0.84-per-share loss this fiscal year.
• Neutral Sentiment: Reported short interest was zero shares as of August 25, unchanged from the prior report. The resulting zero-day short-interest ratio suggests short covering is not a factor influencing the stock’s current move, although the data may be incomplete or anomalous.

Climb Bio Stock Down 6.7%

Shares of CLYM traded down $1.19 during mid-day trading on Wednesday, reaching $16.65. The company had a trading volume of 410,463 shares, compared to its average volume of 939,391. Climb Bio has a 52-week low of $1.54 and a 52-week high of $18.33. The stock has a market capitalization of $956.38 million, a P/E ratio of -20.06 and a beta of 0.08. The stock has a 50 day moving average of $13.59 and a two-hundred day moving average of $10.29.

Climb Bio (NASDAQ:CLYM) last posted its earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.03. On average, sell-side analysts expect that Climb Bio will post -0.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. BTIG Research boosted their price objective on shares of Climb Bio from $19.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, June 11th. Wedbush reaffirmed an “outperform” rating and set a $20.00 price target on shares of Climb Bio in a research report on Wednesday, August 19th. Robert W. Baird set a $21.00 price objective on Climb Bio in a report on Wednesday, May 6th. Truist Financial raised their price objective on Climb Bio from $17.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a report on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $23.08.

Hedge Funds Weigh In On Climb Bio

Several institutional investors have recently made changes to their positions in CLYM. MPM Bioimpact LLC acquired a new position in shares of Climb Bio in the 4th quarter valued at $10,686,000. BlackRock Inc. purchased a new position in Climb Bio in the second quarter valued at $30,708,000. Braidwell LP increased its holdings in Climb Bio by 102.6% in the second quarter. Braidwell LP now owns 3,099,027 shares of the company’s stock valued at $40,411,000 after buying an additional 1,569,352 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Climb Bio by 265.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,923,639 shares of the company’s stock worth $7,695,000 after acquiring an additional 1,396,722 shares during the period. Finally, ADAR1 Capital Management LLC raised its position in shares of Climb Bio by 972.8% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,432,475 shares of the company’s stock worth $5,730,000 after acquiring an additional 1,298,945 shares during the period. 69.76% of the stock is owned by hedge funds and other institutional investors.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.